Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175096305> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3175096305 endingPage "259" @default.
- W3175096305 startingPage "255" @default.
- W3175096305 abstract "INTRODUCTION: Forkhead Transcription Factor 3a (FoxO3a) has been proposed to have a high efficacy to predict the failure of imatinib mesylate (IM) therapy among Chronic Myeloid Leukemia (CML) patients. However, the limited evidence had made this marker remained controversy.
 OBJECTIVES: We aimed to investigate the correlation between the levels of FoxO3a and the risk of treatment failure of IM therapy in CML patients.
 METHODS: A prospective cohort study was carried out between February 2019 and February 2020 in Saiful Anwar Hospital, Malang, Indonesia. All CML patients treated with IM on our hospital during the study period were included. The levels of FoxO3a was determined using the Enzyme-linked immunosorbent assay (ELISA) using Cusabio Biotech Kit (Cusabio Biotech Co., New York, USA). The treatment response was assessed using the European Leukemia criteria. The correlation and effect estimate between the levels of FoxO3a and treatment response of CML patients was assessed using multiple logistic regression.
 RESULTS: 53 CML patients receiving IM in our hospital were included, consisting of 29 patients with good response and 24 patients with non-response. Our study found that CML patients with lower levels of FoxO3a was associated with increased risk to develop treatment failure when treated with IM. Moreover, we also found that higher risk of treatment failure of IM therapy was also found in patients with increased levels of thrombocytes, basophils, and leukocytes, and lower levels of hemoglobin.
 CONCLUSION: We reveal that FoxO3a is the prominent marker to predict the treatment response of CML patients treated with IM." @default.
- W3175096305 created "2021-07-05" @default.
- W3175096305 creator A5034793731 @default.
- W3175096305 creator A5037812739 @default.
- W3175096305 creator A5051682978 @default.
- W3175096305 creator A5084635147 @default.
- W3175096305 creator A5085401315 @default.
- W3175096305 date "2021-04-29" @default.
- W3175096305 modified "2023-09-27" @default.
- W3175096305 title "The Levels of FoxO3a Predict the Failure of Imatinib Mesylate Therapy among Chronic Myeloid Leukemia Patients" @default.
- W3175096305 cites W1978345377 @default.
- W3175096305 cites W2009214080 @default.
- W3175096305 cites W2013307916 @default.
- W3175096305 cites W2021033166 @default.
- W3175096305 cites W2044901721 @default.
- W3175096305 cites W2047462858 @default.
- W3175096305 cites W2059406856 @default.
- W3175096305 cites W2062367811 @default.
- W3175096305 cites W2072875377 @default.
- W3175096305 cites W2074015360 @default.
- W3175096305 cites W2088580357 @default.
- W3175096305 cites W2092851008 @default.
- W3175096305 cites W2104602638 @default.
- W3175096305 cites W2109555166 @default.
- W3175096305 cites W2128610489 @default.
- W3175096305 cites W2144514960 @default.
- W3175096305 cites W2236676365 @default.
- W3175096305 cites W2296146218 @default.
- W3175096305 cites W2329510453 @default.
- W3175096305 cites W2736210861 @default.
- W3175096305 cites W2884698969 @default.
- W3175096305 cites W2884819597 @default.
- W3175096305 cites W2952328820 @default.
- W3175096305 cites W2980571761 @default.
- W3175096305 cites W3013641498 @default.
- W3175096305 doi "https://doi.org/10.3889/oamjms.2021.5852" @default.
- W3175096305 hasPublicationYear "2021" @default.
- W3175096305 type Work @default.
- W3175096305 sameAs 3175096305 @default.
- W3175096305 citedByCount "3" @default.
- W3175096305 countsByYear W31750963052021 @default.
- W3175096305 countsByYear W31750963052022 @default.
- W3175096305 crossrefType "journal-article" @default.
- W3175096305 hasAuthorship W3175096305A5034793731 @default.
- W3175096305 hasAuthorship W3175096305A5037812739 @default.
- W3175096305 hasAuthorship W3175096305A5051682978 @default.
- W3175096305 hasAuthorship W3175096305A5084635147 @default.
- W3175096305 hasAuthorship W3175096305A5085401315 @default.
- W3175096305 hasBestOaLocation W31750963051 @default.
- W3175096305 hasConcept C126322002 @default.
- W3175096305 hasConcept C143998085 @default.
- W3175096305 hasConcept C151956035 @default.
- W3175096305 hasConcept C188816634 @default.
- W3175096305 hasConcept C2777583451 @default.
- W3175096305 hasConcept C2778729363 @default.
- W3175096305 hasConcept C3019892230 @default.
- W3175096305 hasConcept C71924100 @default.
- W3175096305 hasConceptScore W3175096305C126322002 @default.
- W3175096305 hasConceptScore W3175096305C143998085 @default.
- W3175096305 hasConceptScore W3175096305C151956035 @default.
- W3175096305 hasConceptScore W3175096305C188816634 @default.
- W3175096305 hasConceptScore W3175096305C2777583451 @default.
- W3175096305 hasConceptScore W3175096305C2778729363 @default.
- W3175096305 hasConceptScore W3175096305C3019892230 @default.
- W3175096305 hasConceptScore W3175096305C71924100 @default.
- W3175096305 hasIssue "B" @default.
- W3175096305 hasLocation W31750963051 @default.
- W3175096305 hasOpenAccess W3175096305 @default.
- W3175096305 hasPrimaryLocation W31750963051 @default.
- W3175096305 hasRelatedWork W11313001 @default.
- W3175096305 hasRelatedWork W13021636 @default.
- W3175096305 hasRelatedWork W14019567 @default.
- W3175096305 hasRelatedWork W15666944 @default.
- W3175096305 hasRelatedWork W16114088 @default.
- W3175096305 hasRelatedWork W18760892 @default.
- W3175096305 hasRelatedWork W19038098 @default.
- W3175096305 hasRelatedWork W2445216 @default.
- W3175096305 hasRelatedWork W5199437 @default.
- W3175096305 hasRelatedWork W5708660 @default.
- W3175096305 hasVolume "9" @default.
- W3175096305 isParatext "false" @default.
- W3175096305 isRetracted "false" @default.
- W3175096305 magId "3175096305" @default.
- W3175096305 workType "article" @default.